Standard BioTools Inc.
LAB
$1.07
-$0.045-4.04%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 40.80M | 46.72M | 44.97M | 37.21M | 45.54M |
| Total Other Revenue | -- | -- | -- | -- | 921.00K |
| Total Revenue | 40.80M | 46.72M | 44.97M | 37.21M | 45.54M |
| Cost of Revenue | 21.05M | 24.81M | 21.71M | 41.52M | 21.35M |
| Gross Profit | 19.74M | 21.91M | 23.26M | -4.31M | 24.19M |
| SG&A Expenses | 38.71M | 37.59M | 34.40M | 35.77M | 46.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.09M | 76.45M | 69.27M | 77.29M | 84.28M |
| Operating Income | -30.29M | -29.74M | -24.30M | -40.09M | -38.74M |
| Income Before Tax | -26.18M | -33.80M | -26.82M | -45.66M | -32.03M |
| Income Tax Expenses | -151.00K | 272.00K | 118.00K | 55.00K | 128.00K |
| Earnings from Continuing Operations | -26.03M | -34.07M | -26.94M | -45.72M | -32.16M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.03M | -34.07M | -26.94M | -45.72M | -32.16M |
| EBIT | -30.29M | -29.74M | -24.30M | -40.09M | -38.74M |
| EBITDA | -26.12M | -25.78M | -17.93M | -35.69M | -33.54M |
| EPS Basic | -0.07 | -0.09 | -0.07 | -0.12 | -0.27 |
| Normalized Basic EPS | -0.04 | -0.05 | -0.03 | -0.06 | -0.08 |
| EPS Diluted | -0.07 | -0.09 | -0.07 | -0.12 | -0.27 |
| Normalized Diluted EPS | -0.04 | -0.05 | -0.03 | -0.06 | -0.08 |
| Average Basic Shares Outstanding | 378.23M | 374.54M | 371.54M | 372.33M | 294.13M |
| Average Diluted Shares Outstanding | 378.23M | 374.54M | 371.54M | 372.33M | 294.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |